CTO Plus 2023 will feature the latest research and techniques for chronic total occlusions (CTO) and complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation (CRF), will take place February 23-24 at the New York Marriott Marquis in New York, NY.
The Cardiovascular Research Foundation (CRF) announced today that Alexandra Popma, MD, has joined the organization as Executive Director of the CRF Clinical Trials Center.
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine, September 16-19 in Boston. The winner was also presented with the Jon DeHaan Foundation Award for Innovation in Cardiology.
Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery. Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
An analysis from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry found that most patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) in the United States achieved successful MR reduction, and that successful repair was associated with lower mortality and heart failure (HF) hospitalizations at one year post-procedure compared with unsuccessful repair.
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum. The summit will be held on the first day of TCT, the annual scientific symposium of CRF, on Friday, September 16. TCT will take place September 16-19, 2022, in Boston, Massachusetts, at the Boston Convention and Exhibition Center.
Two leaders in cardiovascular disease science, research and education, the American Heart Association (Association) and the Cardiovascular Research Foundation (CRF), are joining forces to strengthen and expand educational opportunities focused on advancing the latest research in cardiovascular disease and interventional therapies. The new alliance to produce joint education programs begins immediately with the organizations’ annual scientific meetings this fall. The Association will present educational programming from its annual Scientific Sessions at TCT, and CRF will deliver educational programming from its annual scientific symposium Transcatheter Cardiovascular Therapeutics (TCT) at the Association’s Scientific Sessions, beginning with TCT 2022, September 16-19 in Boston, and the Association’s Scientific Sessions 2022, November 5-7 in Chicago, respectively.
The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical science that will be presented at TCT 2022. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place September 16-19 in Boston, Massachusetts at the Boston Convention and Exhibition Center.
The TCT Career Achievement Award will be presented to Valentin Fuster, MD, PhD, on September 17, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to an outstanding individual who has made significant contributions to the field of interventional cardiology and transformed patient care through their career endeavors, research pursuits, and mentorship of others.
The TCT Geoffrey O. Hartzler Master Operator Award will be presented to Jean Fajadet, MD, on September 18, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and innovation.
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that they are joining forces to launch the "TCT MedTech Innovation Forum” just before the main sessions of TCT (Transcatheter Cardiovascular Therapeutics) 2022, the annual scientific symposium of CRF. TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. An annual meeting covering cutting-edge research and techniques for structural heart interventions, TVT will take place June 8-10, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
The program for TVT 2022: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 8-10, 2022 at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
Media registration is now open for TCT 2022 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.
CTO Plus 2022 will feature the latest research and techniques for chronic total occlusions (CTO) as well as complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation (CRF), will take place February 24-25, 2022 at the New York Marriott Marquis in New York, NY. Online access to the live cases and discussions will be complimentary. The full program is now available online.
The program for THT 2022: Technology and Heart Failure Therapeutics is now available online. THT is the first-ever conference on technology and heart failure therapeutics from the Cardiovascular Research Foundation (CRF). The meeting, which explores new and emerging treatments and innovative monitoring strategies, will take place February 1-2, 2022 online and in person, at the New York Marriott Marquis in New York, NY.
The Cardiovascular Research Foundation (CRF) is pleased to announce that Lungpacer Medical, a clinical stage medical device company pioneering a diaphragm pacing therapy system for critically ill patients who require mechanical ventilation, has won the TCT 2021 Shark Tank Innovation Competition, which took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine. The winner was also presented with the Jon DeHaan Foundation Award for Interventional Innovation.
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days but through different mechanism. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days.
Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal gastrointestinal (GI) mucosal findings on capsule endoscopy. Dual antiplatelet therapy (DAPT) followed by single anti-platelet therapy (SAPT) led to less GI injury than continued DAPT.
Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis but a higher rate of access-site or access-related vascular complications.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right